Canopy Growth (CGC) Asset Writedowns and Impairment (2020 - 2023)
Canopy Growth (CGC) reported Asset Writedowns and Impairment of $7.9 million for Q2 2023, down 99.42% on a YoY basis from $1.4 billion in Q2 2022, and down 97.14% sequentially from $275.7 million in Q1 2023.
Canopy Growth (CGC) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends
Canopy Growth (CGC) has 4 years of Asset Writedowns and Impairment data on file, last reported at $7.9 million in Q2 2023.
- For the quarter ending Q2 2023, Asset Writedowns and Impairment fell 99.42% year-over-year to $7.9 million; the trailing twelve-month figure through Jun 2023 stood at $379.0 million (down 75.59% YoY), and the FY2023 full-year result was $1.6 billion, up 520.41% from the prior year.
- Asset Writedowns and Impairment slipped to $7.9 million in Q2 2023, from $275.7 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 billion in Q2 2022 to a low of -$809503.1 in Q3 2021.
- A 4-year average of $209.4 million and a median of $76.3 million in 2021 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment surged 10927.04% in 2022 and sank 99.42% in 2023, its largest moves.
- Tracing CGC's Asset Writedowns and Impairment over 4 years: stood at $228.7 million in 2020, then tumbled by 88.71% to $25.8 million in 2021, then sank by 69.77% to $7.8 million in 2022, then gained by 0.88% to $7.9 million in 2023.
- Business Quant data shows CGC's Asset Writedowns and Impairment at $7.9 million in Q2 2023, $275.7 million in Q1 2023, and $7.8 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | Canopy Growth | 281.68 Mn | 15.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 7.88 Mn |
| Jun 30, 2023 | 7.88 Mn |
| Mar 31, 2023 | 275.71 Mn |
| Mar 31, 2023 | 275.71 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Sep 30, 2022 | 87.65 Mn |
| Sep 30, 2022 | 87.65 Mn |
| Jun 30, 2022 | 1.35 Bn |
| Jun 30, 2022 | 1.35 Bn |
| Mar 31, 2022 | 173.45 Mn |
| Mar 31, 2022 | 173.45 Mn |
| Dec 31, 2021 | 25.83 Mn |
| Dec 31, 2021 | 25.83 Mn |
| Sep 30, 2021 | -809,503.09 |
| Sep 30, 2021 | -809,503.09 |
| Jun 30, 2021 | 66.47 Mn |
| Jun 30, 2021 | 66.47 Mn |
| Mar 31, 2021 | 76.32 Mn |
| Mar 31, 2021 | 76.32 Mn |